Immutep doses first patient in TACTI-002 Phase II trial

8 March 2019 |

Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA® (pembrolizumab) in head and neck squamous cell carcinoma (2nd line) and non-small cell lung cancer (1st and 2nd line).

The study is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada), as announced to the market in March 2018.

The study will take place in up to 109 patients in up to 13 study centres across Australia, Europe and the United States.

Read the full press release


News & opinion

Member Directory